COVID-19 Updates to CHEST Anticoagulation Guidelines

- In the absence of contraindication, all acutely hospitalized patients with COVID-19 should receive thromboprophylaxis therapy.

- Low-molecular-weight heparin or fondaparinux should be used for thromboprophylaxis over unfractionated heparin and direct oral anticoagulants.

- There are insufficient data to justify routine increased intensity anticoagulant dosing in hospitalized or critically ill COVID-19 patients.

- Recommend only inpatient thromboprophylaxis for COVID-19 patients.

- In critically ill COVID-19 patients, suggest against routine ultrasound screening for the detection of asymptomatic DVT.

- For critically ill COVID-19 patients with proximal DVT or PE, recommend parenteral anticoagulation therapy with therapeutic weight adjusted low-molecular-weight heparin or fondaparinux over unfractionated heparin.